Researchers showed that a combination immunotherapy platform utilizing low dose chemotherapy combined with oncolytic virotherapy increased tumor-infiltrating lymphocytes, in otherwise immune-bare tumors, allowing 60% of mice to achieve durable tumor regression when treated with immune checkpoint blockade.
[Communications Biology]
6445218
{6445218:NZHC5FIK}
apa
50
1
164476
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
